1036991-40-8

Basic information

• Product Name: 1,5-Dimethyl-1H-pyrazole-4-boronic acid,pinacol ester
• Synonyms: 1,5-Dimethyl-1H-pyrazole-4-boronic acid,pinacol ester;1,5-Dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole;1,5-DiMethyl-1H-pyrazol-4-ylboronic acid,pinacol ester;1H-Pyrazole, 1,5-diMethyl-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-;1,5-diMethyl-4-(tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole;1,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole
• CAS NO: 1036991-40-8
• Molecular Formula: C₁₁H₁₉BN₂O₂
• Molecular Weight: 222.09
• Mol File: 1036991-40-8.mol

Chemical Properties

• Melting Point: 87 °C
• Boiling Point: 322.3±30.0 °C(Predicted)
• Appearance: /
• Density: 1.04±0.1 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: 2.66±0.10(Predicted)
• CAS DataBase Reference: 1,5-Dimethyl-1H-pyrazole-4-boronic acid,pinacol ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1,5-Dimethyl-1H-pyrazole-4-boronic acid,pinacol ester(1036991-40-8)
• EPA Substance Registry System: 1,5-Dimethyl-1H-pyrazole-4-boronic acid,pinacol ester(1036991-40-8)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• RIDADR: 2811
• WGK Germany: 3
• HazardClass: 6.1
• PackingGroup: Ⅲ
• Hazardous Substances Data: 1036991-40-8(Hazardous Substances Data)

Usage

Uses

1,5-Dimethyl-1H-pyrazole-4-boronic acid,pinacol ester

Upstream product

• 936250-20-3 3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 
• 74-88-4 methyl iodide 

Downstream Products

• 1046831-25-7 3-(1,5-dimethyl-1H-pyrazol-4-yl)-1-(phenylsulfonyl)-5-(1,4-dioxaspiro[4.5]decan-8-yl)-1H-pyrrolo[2,3-b]pyridine 
• 1310532-54-7 5-(1,5-dimethyl-1H-pyrazol-4-yl)-2-fluorobenzaldehyde 
• 1310531-20-4 5-{1-tert-butyl-2-[5-(1,5-dimethyl-1H-pyrazol-4-yl)-2-[1,2,4]triazol-1-yl-phenyl]-1H-benzoimidazol-5-yl}pyrimidin-2-ylamine 
• 1310532-55-8 5-(1,5-dimethyl-1H-pyrazol-4-yl)-2-[1,2,4]triazole-1-ylbenzaldehyde 
• 1350324-05-8 tert-butyl 3-[(1S)-1-(2-chloro-6-{[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy}-3-fluorophenyl)ethyl]-5-(1,5-dimethyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine-1-carboxylate 
• 1407831-22-4 (4R)-6-(4-chlorophenyl)-8-(1,5-dimethyl-1H-pyrazol-4-yl)-1,4-dimethyl-5,6-dihydro-4H-benzo[b][1,2,4]triazolo[4,3-d][1,4]diazepine 
• 1578246-19-1 4-(1,5-dimethyl-1H-pyrazol-4-yl)-2-methoxyaniline 
• 1578244-06-0 N²-(4-(1,5-dimethyl-1H-pyrazol-4-yl)-2-methoxyphenyl)-N⁸-neopentylpyrido[3,4-d]pyrimidine-2,8-diamine 
• 1578246-47-5 N-(4-(1,5-dimethyl-1H-pyrazol-4-yl)-2-methoxyphenyl)formamide 

Relevant articles and documents

NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE

The present invention embodiments relate to compound of Formula I or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates in certain embodiments to the use of the compounds of Formula I as TDO2 inhibitors. The invention also relates in certain embodiments to the use of the compounds of Formula I for the treatment and/or prevention of cancer, neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and Huntington's disease, chronic viral infections such as HCV and HIV, depression, and obesity. The invention also relates in certain embodiments to a process for manufacturing compounds of Formula I.

CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES

Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including, but not limited to, malignant melanomas, solid tumors, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, chronic myelogenous leukemia, leukemias, papillary thyroid carcinoma, non-small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, diabetic retinopathy, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocytosis, mast cell leukemia, and diseases caused by PDGFR-α kinase, PDGFR-β kinase, c-KIT kinase, cFMS kinase, c-MET kinase, and oncogenic forms, aberrant fusion proteins and polymorphs of any of the foregoing kinases.